A Study to Evaluate and Compare Effectiveness Among New Measuring Methods to Find Minimal Residual Disease Following Stem Cell Transplant for Multiple Myeloma


About this study

The purpose of this study is to evaluate and compare the effectiveness of new methods of measuring more accurately for minimal residual disease following bone marrow/stem cell transplant in patients who have multiple myeloma. The study will also assess patient perceived quality of life in connection to the use of intensive treatments.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

  • Has symptomatic Multiple Myeloma
  • Has undergone a single Autologous Stem Cell Transplant between 07/1/2015-06/30/2017 following any standard induction therapy at Mayo Clinic, Rochester
  • Has simultaneously donated peripheral blood and bone marrow samples for research purposes through IRB # 521-93 around day 90 (±30 days) post-ASCT
  • Has achieved a complete response after ASCT as assessed by the IMWG 2008 response criteria 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Prashant Kapoor, M.D.

Closed for enrollment

Contact information:

Prashant Kapoor M.D.



More information


Publications are currently not available

Mayo Clinic Footer